AMA Announces Approval for Category lll CPT Code for Real-time Fluorescence Wound Imaging

November 4, 2019 -Forthcoming Category lll CPT Code Reflects the Published Clinical Evidence and a Determination of Significant Value of Real-Time Fluorescence Imaging Across the Wound Care Treatment Pathway

TORONTO, Canada – (November 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has

Clinical Results from the MolecuLight i:X® Fluorescence Imaging System are Featured in Two Clinical Talks and Seven Posters at the SAWC Fall 2019 Annual Conference

October 11, 2019 -

Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for Chronic Wound Management

LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds and its i:X point-of-care fluorescence imaging

Results from Clinical Studies using MolecuLight i:X® Fluorescence Imaging System Featured Prominently at the Wounds Canada 2019 Annual Conference

October 4, 2019 -

Point-of-Care Fluorescence Imaging for Chronic Wounds and its Significant Clinical Benefits are Featured at the Largest Canadian Wound Care Conference in 5 Clinical Talks and Posters

NIAGARA FALLS, Canada and TORONTO, Canada – (October 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization

Published Study Finds 9/10 Chronic Wound Patients Likely to Have Received More Appropriately Triaged Care with Information from the MolecuLight i:X® Imaging Device

September 13, 2019 -Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound’s Bacterial Burden that Significantly Impacted Treatment Decisions Read More

Oxford Finance LLC Provides $7.5M USD Term Loan to MolecuLight® Inc. to Support Global Commercial Expansion

August 19, 2019 -

TORONTO, Canada – (August 20, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, announced it has secured a $7.5 million USD term loan from Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services

photonamic GmbH & Co. KG (Germany) Acquires the Oncology Business from MolecuLight® Inc. (Canada)

August 14, 2019 -

photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the

MolecuLight® Inc.’s first-of-its-kind handheld fluorescence imaging device receives FDA De Novo clearance for US wound care market

August 14, 2018 -MolecuLight Inc. achieved a major regulatory milestone permitting expansion into the United States market. FDA has granted De Novo clearance for the ground-breaking wound fluorescence imaging device, the MolecuLight i:X.  Read More

MolecuLight announces appointment of Anil Amlani as CEO

October 17, 2017 -

TORONTO, CANADA.  MolecuLight, a global leader in fluorescence image-guidance solutions, is pleased to announce the appointment of industry veteran Anil Amlani as Chief Executive Officer effective September 29, 2017.

William Wignall, Chairman of the Board at MolecuLight, commented, “The Board is delighted to welcome Anil as MolecuLight’s new CEO. Anil